Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

Related Articles by Review for PubMed (Select 17697207)

1.

Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy.

Palmieri O, Latiano A, Bossa F, Vecchi M, D'IncĂ  R, Guagnozzi D, Tonelli F, Cucchiara S, Valvano MR, Latiano T, Andriulli A, Annese V.

Aliment Pharmacol Ther. 2007 Sep 1;26(5):737-45. Erratum in: Aliment Pharmacol Ther. 2007 Sep 15;26(6):968.

2.

Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease.

Van Dieren JM, Hansen BE, Kuipers EJ, Nieuwenhuis EE, Van der Woude CJ.

Aliment Pharmacol Ther. 2007 Sep 1;26(5):643-52. Review.

3.

Review article: thiopurines in inflammatory bowel disease.

Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW.

Aliment Pharmacol Ther. 2006 Sep 1;24(5):715-29. Review.

4.

Pharmacogenetics of thiopurines in inflammatory bowel disease.

Derijks LJ, Wong DR.

Curr Pharm Des. 2010;16(2):145-54. Review.

PMID:
20205660
5.

Thiopurine therapy in inflammatory bowel disease.

Ha C, Dassopoulos T.

Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):575-88. doi: 10.1586/egh.10.59. Review.

PMID:
20932143
6.

Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.

Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR.

Dig Liver Dis. 2005 Apr;37(4):282-97. Review.

PMID:
15788214
7.

Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease.

Dong XW, Zheng Q, Zhu MM, Tong JL, Ran ZH.

World J Gastroenterol. 2010 Jul 7;16(25):3187-95. Review.

8.

Clinical pharmacology and pharmacogenetics of thiopurines.

Sahasranaman S, Howard D, Roy S.

Eur J Clin Pharmacol. 2008 Aug;64(8):753-67. doi: 10.1007/s00228-008-0478-6. Epub 2008 May 28. Review.

PMID:
18506437
9.

Review article: interactions between genotype and response to therapy in inflammatory bowel diseases.

Herrlinger KR, Jewell DP.

Aliment Pharmacol Ther. 2006 Nov 15;24(10):1403-12. Review.

10.

On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance.

Van Asseldonk DP, de Boer NK, Peters GJ, Veldkamp AI, Mulder CJ, Van Bodegraven AA.

Curr Drug Metab. 2009 Nov;10(9):981-97. Review.

PMID:
20214590
11.

Drug monitoring in inflammatory bowel disease: helpful or dispensable?

Bruns T, Stallmach A.

Dig Dis. 2009;27(3):394-403. doi: 10.1159/000228580. Epub 2009 Sep 24. Review.

PMID:
19786771
12.

Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD.

de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ.

Nat Clin Pract Gastroenterol Hepatol. 2007 Dec;4(12):686-94. Review.

PMID:
18043678
13.

Inosine triphosphate pyrophosphatase 94C>A polymorphism: clinical implications for patients with systemic lupus erythematosus treated with azathioprine.

Yamamoto K, Okada Y, Nakamura K, Hiromura K, Nojima Y, Nakamura T.

Expert Opin Drug Saf. 2010 May;9(3):447-57. doi: 10.1517/14740330903544474. Review.

PMID:
20367526
14.

Pharmacogenetics of inflammatory bowel disease.

Kelleher D, Farrell R, McManus R.

Novartis Found Symp. 2004;263:41-53; discussion 53-6, 211-8. Review.

PMID:
15669633
15.

Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.

Shah RR.

Expert Opin Drug Saf. 2005 Jan;4(1):103-28. Review.

PMID:
15709902
16.

Use of thiopurines in inflammatory bowel disease.

Frei P, Biedermann L, Nielsen OH, Rogler G.

World J Gastroenterol. 2013 Feb 21;19(7):1040-8. doi: 10.3748/wjg.v19.i7.1040. Review.

17.

Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides.

Duley JA, Florin TH.

Ther Drug Monit. 2005 Oct;27(5):647-54. Review.

PMID:
16175140
18.

Review article: practical management of inflammatory bowel disease patients taking immunomodulators.

Siegel CA, Sands BE.

Aliment Pharmacol Ther. 2005 Jul 1;22(1):1-16. Review.

19.

Optimizing conventional therapy for inflammatory bowel disease.

Schwartz M, Cohen R.

Curr Gastroenterol Rep. 2008 Dec;10(6):585-90. Review.

PMID:
19006615
20.

Pharmacogenomics in inflammatory bowel disease.

Egan LJ, Derijks LJ, Hommes DW.

Clin Gastroenterol Hepatol. 2006 Jan;4(1):21-8. Review.

PMID:
16431300
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk